Tumour necrosis factor- blockers: potential limitations in the management of advanced endometriosis? A Case Report
article
OA: bronze
CC0
⤵ 22 in-corpus citations
Abstract
Several studies have shown that tumour necrosis factor (TNF)-alpha levels are increased in the peritoneal fluid of women with endometriosis, with correlation between TNF-alpha concentrations and the degree of disease. It is also likely that elevation of peritoneal fluids' TNF-alpha levels may play a role in the pathogenesis of infertility associated with endometriosis. Use of drugs such as etanercept, a TNF-alpha receptor immunoglobulin fusion protein which inhibits TNF-alpha activity, showed in an animal study to reduce the severity of the disease, and the size of endometriotic foci. TNF-alpha blockers were recommended as a possible new line of therapy for endometriosis. Our case involved a 35-year-old Para 0, with rheumatic arthritis and stage 4 endometriosis. After 6 years of constant use of etanercept, she showed no improvement of endometriosis as demonstrated at laparoscopy. However, she underwent a successful IVF after the first attempt. TNF-alpha-blocker medications might not be beneficial for patients with advanced endometriosis. However, we cannot exclude the possible effect of these medications on early-stage endometriosis, and further study is required. Some of the immunologic abnormalities in the pelvis of patients with endometriosis could be the consequence of the disease and not the cause, and possibly suppression of immune cells and their products may not have a major effect on endometriotic lesions at an advanced stage. This also could explain why suppression of TNF-alpha showed no effect on infertility. However, use of TNF-alpha-blockers before IVF might increase the success rate in advanced endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (15)
- Aromatase expression in endometriosis via openalex
- Aromatase expression in endometriosis. via openalex
- Effect of tumor necrosis factor-α on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system via openalex
- Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons via openalex
- Estradiol Amplifies Interleukin-1-Induced Monocyte Chemotactic Protein-1 Expression by Ectopic Endometrial Cells of Women with Endometriosis via openalex
- Estradiol Amplifies Interleukin-1-Induced Monocyte Chemotactic Protein-1 Expression by Ectopic Endometrial Cells of Women with Endometriosis<sup>1</sup> via openalex
- Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin- releasing hormone agonist via openalex
- Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model via openalex
- Medical Therapy for Endometriosis via openalex
- Medical Therapy of Endometriosis via openalex
- Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial via openalex
- Revised American Society for Reproductive Medicine classification of endometriosis: 1996 via openalex
- Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis via openalex
- Tumour necrosis factor-α, interleukin-6 and interleukin-8 do not promote adhesion of human endometrial epithelial cells to mesothelial cells in a quantitative in vitro model* via openalex
- Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. via openalex
Cited by (22)
- Peri-implantation treatment with TNF-α inhibitor for endometriosis and/or adenomyosis women undergoing frozen-thawed embryo transfer: A retrospective cohort study 2024
- The Pathological Role of miRNAs in Endometriosis 2023
- Prevalent innate and adaptive immune mechanisms in endometriosis 2021
- Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy 2020
- Reduced inflammatory state promotes reinnervation of endometriotic-like lesions in TNFRp55 deficient mice 2019
- Propuesta de un nuevo modelo microquirúrgico para el estudio de la endometriosis inducida en rata Wistar. Resultados Preliminares 2017
- Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma 2017
- Emerging treatment of endometriosis 2015
- On-label and off-label drug use in the treatment of endometriosis 2015
- rhTNFR: Fc Suppresses the Development of Endometriosis in a Mouse Model by Downregulating Cell Proliferation and Invasiveness 2015
- A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis 2012
- Regression of endometrial autografts in a rat model of endometriosis treated with etanercept 2011
- Effect of anti-TNF- Effect of anti-TNF- Effect of anti-TNF- Effect of anti-TNF- Effect of anti-TNF- a on peritoneal endometrial implants of rats 2011
- Efeito do anti-TNF-α em implantes endometriais no peritônio de ratas 2011
- Efficacy of anti-tumor necrosis factor therapy on endometriosis in an experimental rat model 2010
- Surgical Management Options for Patients with Infertility and Endometriosis 2010
- Newer treatment modalities in endometriosis: systematic review 2009
- Treatment strategies for endometriosis 2008
- Pathogenic mechanisms in endometriosis-associated infertility 2008
- Genetic variation in tumour necrosis factor and lymphotoxin is not associated with endometriosis in an Australian sample 2007
- Endometriosis and Adenomyosis 2007
- Serum and peritoneal abnormalities in endometriosis: potential use as diagnostic markers. 2006
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:15:18.313808+00:00
License: CC0
· commercial use OK